DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of ...
Neurocrine Biosciences Presents New Clinically Meaningful Response Data On Treatment Of Tardive Dyskinesia, Reinforcing The Efficacy Of INGREZZA® (Valbenazine) Capsules Across A Broad Range Of ...
Hosted on MSN
Neurocrine unveils first expert guidance for tardive dyskinesia care in long-term facilities
Neurocrine Biosciences (NASDAQ:NBIX) on Thursday announced new expert consensus recommendations aimed at improving the screening, diagnosis and treatment of tardive dyskinesia (TD) among older adults ...
Teva (TEVA) Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football touchdowns to raise awareness and understanding of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results